Objective: Aim of this study is to report on basal clinical phenotype and follow up after diagnosis, of patients with 17β-hydroxysteroid-dehydrogenase type 3 (17β-HSD3) deficiency in Italy. Setting: Pediatric Endocrine Departments, University Hospitals. Patients: The cases of 5 Italian subjects affected by 17β-HSD3 deficiency are presented in this study. Interventions: Laboratory and genetic assessment. Gonadectomy and female sex assignment (4 patients) or GnRH analog therapy to regress puberty and gender identity disorder (1 patient). Results: Presentation lasted from pregnancy (pre-natal diagnosis of a 46,XY fetus with female external genitalia) to infancy (inguinal hernia containing testes/clitoromegaly) and adolescence (virilisation). All subjects but one (subject 1, Central-Northern Italy) were from small areas of Southern Italy. Endocrine data (baseline and/or stimulated testosterone/A4-androstenedione ratio) were informative. Two girls were homozygous for 17β-HSD3 gene mutations (G289S/G289S; R80W/R80W), while the others were compound heterozygous (IVS325+4 A>T/A203V; L212Q/M235V; R80W/A235E). Four patients were confirmed as females and were well-adjusted with assigned sex; gender identity disorder improved during treatment with GnRH analog in the last subject. Conclusions: 17βHSD3 deficiency may present from pregnancy to puberty for different clinical issues. Albeit testosterone/A4-androstenedione ratio represents the most accurate endocrine marker to diagnose the disorder, hCG-stimulation is mandatory in pre-puberty. Molecular analysis of 17β-HSD3 gene should be performed to confirm the diagnosis. Temporary GnRH analog treatment may regress gender identity disorder and provide time to confirm or change the birth sex assignment. Female individuals seems to be compliant with their sex, providing that virilisation does not occur. In Italy, the disorder seems to be more prevalent in the Southern regions and shows genetic heterogeneity.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Hughes IA, Houk C, Ahmed SF, Lee PA; LWPES Consensus Group; ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child 2006, 91: 554–63.
Faienza MF, Giordani L, Delvecchio M, Cavallo L. Clinical, endocrine, and molecular findings in 17beta-hydroxysteroid dehydrogenase type 3 deficiency. J Endocrinol Invest 2008, 31: 85–91.
Bertelloni S, Dati E, Hiort O. Diagnosis of 17β-hydroxysteroid dehydrogenase deficiency: a review. Expert Review Endocrinol Metab 2009, 4: 53–65.
Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroditism caused by mutations of testicular 17beta-hydroxysteroid dehydrogenase 3. Nat Genet 1994, 7: 34–9.
Andersson S, Geissler WM, Wu L, et al. Molecular genetics and pathophysiology of 17beta-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab 1996, 81: 130–6.
Mendonca BB, Inacio M, Arnhold IJ, et al. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 2000, 79: 299–309.
Lee YS, Kirk JM, Stanhope RG, et al. Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls. Clin Endocrinol (Oxf) 2007, 67: 20–8.
Sinnecker GH, Hiort O, Dibbelt L, et al. Phenotypic classification of male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Am J Med Genet 1996, 63: 223–30.
Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006, 29: 581–93.
Sane K, Pescovitz OH. The clitoral index: a determination of clitoral size in normal girls and in girls with abnormal sexual development. J Pediat 1992, 120: 264–6.
Boehmer ALM, Brinkmann AO, Sandkuijl LA, et al. 17beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab 1999, 84: 4713–21.
Twesten W, Holterhus P, Sippell WG, et al. Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency. Horm Res 2000, 53: 26–31.
Crofton PM, Evans AE, Groome NP, Taylor MR, Holland CV, Kelnar CJ. Inhibin B in boys from birth to adulthood: relationship with age, pubertal stage, FSH and testosterone. Clin Endocrinol (Oxf) 2002, 56: 215–21.
Moghrabi N, Hughes IA, Dunaif A, Andersson S. Deleterious mis-sense mutations and silent polymorphism in the human 17β-hydroxysteroid dehydrogenase 3 gene (HSD17β3). J Clin Endocrinol Metab 1998, 83: 2855–60.
Cassorla FG, Golden SM, Johnsonbaugh RE, Heroman WM, Loriaux DL, Sherins RJ. Testicular volume during early infancy. J Pediatr 1981, 99: 742–3.
Taranger J, Engström I, Lichtenstein H, Svennberg-Redegren I. VI. Somatic pubertal development. Acta Paediatr Scand Suppl 1976, 258: 121–35.
Parisi MA, Ramsdell LA, Burns MW, et al. A Gender Assessment Team: experience with 250 patients over a period of 25 years. Genet Med 2007, 9: 348–57.
18. Hughes IA. Disorders of sex development: a new definition and classification. Best Pract Res Clin Endocrinol Metab 2008, 22: 119–34.
Rosler A. Steroid 17[beta]-hydroxysteroid dehydrogenase deficiency in man: An inherited form of male pseudohermaphroditism. J Steroid Biochem Mol Biol 1992, 43: 989–1002.
Balducci R, Toscano V, Wright F, et al. Familial male pseudohermaphroditism with gynaecomastia due to 17beta-hydroxysteroid dehydrogenase deficiency. A report of 3 cases. Clin Endocrinol (Oxf) 1985, 23: 439–44.
Latronico AC, Arnhold IJ. Inactivating mutations of LH and FSH receptors — from genotype to phenotype. Pediatr Endocrinol Rev 2006, 4: 28–31.
Yalinkaya A, Yayla M, Erdemoglu M. Prenatal diagnosis of a fetus with androgen insensitivity syndrome (AIS). Prenat Diagn 2007, 27: 856–7.
Andersson AM. Inhibin B in the assessment of seminiferous tubular function. Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14: 389–97.
Bilbao JR, Loridan L, Audì L, Gonzalo E, Castaño L. A novel mis-sense (R80W mutation in 17β-hydroxysteroid dehydrogenase type 3 gene associated with male pseudohermaphroditism. Eur J Endocrinol 1998, 139: 330–3.
Rashid HH, Cos LR, Weinberg E, Messing EM. Testicular microlithiasis: a review and its association with testicular cancer. Urol Oncol 2004, 22: 285–9.
Cools M, Drop SL, Wolffenbuttel KP, Oosterhuis JW, Looijenga LH. Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev 2006, 27: 468–84.
Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA. 17β-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite. Fertil Steril 2008, 89: 228.e13-17.
Margiotti K, Kim E, Pearce CL, Spera E, Novelli G, Reichardt JK. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 2002, 53: 65–8.
Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav 2005, 34: 399–410.
Hiort O, Reinecke S, Thyen U, et al. Puberty in disorders of somatosexual differentiation. J Pediatr Endocrinol Metab 2003, 16: 297–306.
Cohen-Kettenis PT, Delemarre-van de Waal HA, Gooren LJ. The Treatment of Adolescent Transsexuals: Changing Insights. J Sex Med 2008, 5: 1892–7.
Rights and permissions
About this article
Cite this article
Bertelloni, S., Balsamo, A., Giordani, L. et al. 17β-Hydroxysteroid dehydrogenase-3 deficiency: From pregnancy to adolescence. J Endocrinol Invest 32, 666–670 (2009). https://doi.org/10.1007/BF03345738
- 17β-hydroxysteroid dehydrogenase type 3 deficiency
- 17β-hydroxysteroid dehydrogenase type 3 gene
- disorders of sex development
- male/female sex reversal
- testotesterone/Δ4-androstenedione ratio